Target | Intervention | Phase | Treated Cancers | Primary outcome measures | Clinical Trials Identifier | Status |
---|---|---|---|---|---|---|
Mesothelin | CAR T cells alone | I | Metastatic pancreatic ductal adenocarcinoma (PDAC) | Number of adverse events | NCT01897415 | Completed (Well-tolerated and showed preliminary evidence of antitumor efficacy in pancreatic cancer) |
CAR T cells + fludarabine, cyclophosphamide & aldeslekin | I/II | Metastatic cancers (PDAC, cervical, lung, ovarian & mesothelioma) | Frequency and severity of adverse events & objective response rate (ORR) | NCT01583686 | Recruiting | |
CAR T cells with/without cyclophosphamide | I | Unresectable/ Metastatic PDAC | Number of participants with adverse events | NCT03323944 | Active, not recruiting | |
CAR T cells with/without cyclophosphamide | I | Metastatic PDAC, epithelial ovarian cancer, & mesothelioma | Number of adverse events | NCT02159716 | Completed (No acute adverse events were observed) | |
CEA | Anti-CEA CAR-T cells | Ib | Liver metastases | Number of participants with adverse events | NCT02850536 | Active, not recruiting |
II | Metastatic colorectal cancer | Number of participants with adverse events | NCT02959151 | Recruiting | ||
I | Lung cancer Colorectal cancer Gastric cancer Breast cancer PDAC | Toxicity profile and number of participants with adverse events | NCT02349724 | Recruiting | ||
I | PDAC | Number of patients with tumor response | NCT03267173 | Recruiting | ||
MUC-1 | Anti-MUC-1 CAR T cells | I/II | Hepatocellular carcinoma Non-small cell lung cancer PDAC Triple-negative invasive breast cancer | Adverse events associated with the administration of anti-MUC-1 CAR T cells | NCT02587689 | Recruiting |
I/II | Malignant glioma of brain Colorectal cancer Gastric cancer | Adverse events associated with the administration of anti-MUC-1 CAR T cells | NCT02617134 | Recruiting | ||
Anti-CTLA-4/PD-1 expressing MUC1-CAR-T cells | I/II | Advanced solid tumor | Safety profile of CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells | NCT03179007 | Recruiting | |
FAP | Adoptive transfer of re-directed FAP-specific T cells | I | Malignant pleural mesothelioma | Safety profile | NCT01722149 | Active, not recruiting |